#biotech
Related Stories (20)
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026UniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026BioNTech to shutter three sites in Germany as no buyers emerge - Reuters
BioNTech to shutter three sites in Germany as no buyers emerge Reuters
September 28, 2026Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on - Reuters
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on Reuters
September 21, 2026Legend Biotech taps Novartis veteran Zhang as CEO - reuters.com
Legend Biotech taps Novartis veteran Zhang as CEO reuters.com
September 15, 2026Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - Reuters
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Reuters
September 3, 2026Moderna shares double as cancer vaccine data rekindles investor hopes - Reuters
Moderna shares double as cancer vaccine data rekindles investor hopes Reuters
August 19, 2026VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results Reuters
August 19, 2026Moderna shares surge as melanoma vaccine with Merck succeeds in large trial - reuters.com
Moderna shares surge as melanoma vaccine with Merck succeeds in large trial reuters.com
August 19, 2026Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition - Reuters
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition Reuters
August 6, 2026Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth - Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth Reuters
August 5, 2026GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal - Reuters
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal Reuters
July 30, 2026Tempus to buy cancer test maker Personalis for $1.5 billion - Reuters
Tempus to buy cancer test maker Personalis for $1.5 billion Reuters
July 20, 2026Vertex to buy Crinetics for $10 billion in rare-diseases push - Reuters
Vertex to buy Crinetics for $10 billion in rare-diseases push Reuters
July 6, 2026Abivax nears $11 billion valuation after fundraising eases M&A pressure - Reuters
Abivax nears $11 billion valuation after fundraising eases M&A pressure Reuters
July 1, 2026French biotech company Ipsen to buy Kartos Therapeutics for $450 million - Reuters
French biotech company Ipsen to buy Kartos Therapeutics for $450 million Reuters
June 29, 2026AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push - Reuters
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push Reuters
June 22, 2026Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO Reuters
June 11, 2026Related Pages (13)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Replimune’s drug for advanced skin cancer fails to win FDA nod again
By Padmanabhan Ananthan and Sruthi Narasimha Chari April 10 (Reuters) – The U.S. Food and Drug Administration on Friday declined to approve Replimune’s drug for advanced skin cancer, citing insuffici
Henrietta Lacks: Family of woman whose cells were 'stolen' settles second lawsuit
The family of a black woman whose cervical cells were harvested in 1951 without her knowledge and replicated infinitely ever since has reached a settlement with a second biotech company. The Switzerl